Skip to main
ACIU

AC Immune (ACIU) Stock Forecast & Price Target

AC Immune (ACIU) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AC Immune is a clinical stage biopharmaceutical company that specializes in developing precision medicine for neurodegenerative diseases. Their pipeline consists of several promising candidates, including ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, and ACI-7104.056, all targeting misfolded proteins associated with neurodegeneration. The company's partnerships with major pharmaceutical companies, such as Takeda and Eli Lilly, provide a strong foundation for future success. The recent promising readouts for its AD and PD programs, along with a strong cash position expected to fund operations through 2027, make AC Immune a strong investment opportunity in the biopharmaceutical sector.

Bears say

AC Immune is heavily reliant on the success of their pipeline, particularly the ACI-24.060 and Crenezumab treatments for Alzheimer's disease, with upcoming data releases in 1H26. While promising immunogenicity data has been seen for the ACI-24 vaccine, the lack of ARIA-E events in the trial is concerning and could potentially hinder the clinical efficacy of the treatment. Additionally, the company's focused resources on targeting misfolded proteins may limit their potential for diversification and put them at risk if there are any setbacks in their pipeline.

AC Immune (ACIU) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AC Immune and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AC Immune (ACIU) Forecast

Analysts have given AC Immune (ACIU) a Strong Buy based on their latest research and market trends.

According to 1 analysts, AC Immune (ACIU) has a Strong Buy consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AC Immune (ACIU)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.